Gossypol, a BH3 mimetic, induces apoptosis in chronic lymphocytic leukemia cells

Kumudha Balakrishnan,1 William G. Wierda,2 Michael J. Keating,2 and Varsha Gandhi1,2

Departments of 1Experimental Therapeutics and 2Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston

Gossypol, a cottonseed extract derivative, acts as a BH3-mimetic, binding to the BH3 pocket of antiapoptotic proteins and displacing pro-death partners to induce apoptosis. However, knowledge on the molecular underpinnings of its downstream effects is limited. Since chronic lymphocytic leukemia (CLL) cells express high levels of antiapoptotic proteins that act as a survival mechanism for these replicationally quiescent lymphocytes, we investigated whether gossypol induces apoptosis in these cells and what mechanism underlies gossypol-mediated cytotoxicity. Gossypol induced cell death in a concentration- and time-dependent manner; 24-hour incubation with 30 μM gossypol resulted in 50% cell death (median; range, 10%-80%; n = 47) that was not abrogated by pan-specific caspase inhibitor. Starting at 4 hours, the mitochondrial outer membrane was significantly permeabilized (median, 77%; range, 54%-93%; n = 15). Mitochondrial outer membrane permeabilization (MOMP) was concurrent with increased production of reactive oxygen species (ROS); however, antioxidants did not abrogate gossypol-induced cell death. Mitochondrial membrane permeabilization was also associated with loss of intracellular adenine triphosphate (ATP), activation of BAX, and release of cytochrome c and apoptosis-inducing factor (AIF), which was translocated to the nucleus. Blocking AIF translocation resulted in a decreased apoptosis, suggesting that AIF contributes to gossypol-mediated cytotoxicity in CLL lymphocytes. (Blood. 2008;112:1971-1980)

Introduction

Gossypol, a natural product derived from cottonseed extracts, was originally extensively investigated in China as a male contraceptive agent.1 It exhibits a type of enantiomerism that arises from restricted rotation: the (−)-gossypol isomer showed greater cytotoxicity than the (+)-isomer in several human cancer cell lines.2 To reduce toxicity, structural modifications in the (−)-gossypol isomer led to the analog apogossypol, which lacks the reactive aldehydic groups and displays proapoptotic activity comparable with that of gossypol; another derivative, gossypolone, demonstrates lower cytotoxicity than the parent compound.3 The success of these agents resulted in the development of additional analogs, such as the L-isomer of gossypol, AT-101,5 and ABT-737, which was designed on the basis of structure activity-based studies.6,7

The gossypol isomers and analogs exhibited inhibitory activity against a wide range of human carcinoma cell lines and in tumor xenograft models.8-11 However, these and other investigations illustrated different actions of this agent, and knowledge on the molecular underpinnings of its biologic effects is still limited.

Early studies in HeLa cells demonstrated that the cytotoxicity of gossypol was based on its inhibitory activity on DNA synthesis through DNA polymerases alpha and beta12 or on topoisomerases.13 Gossypol’s effect on DNA synthesis, leading to S-phase arrest, was specific: no effects on RNA and protein syntheses were observed.14 In concordance with the concept of DNA-directed actions, gossypol appears to play a significant role in the killing of tumor cells by inhibiting cellular proliferation15,16 and by modulating the expression of cell cycle–regulatory proteins Rb and cyclin D1 in human mammary cancer cells and in cyclin D1–transfected human fibrosarcoma cells.17 Consistently, (−)-gossypol caused growth suppression of human prostate cancer cells by down-regulation of cyclin D1, Rb, CDK4, and CDK6 and by up-regulation of p21 and TGF-beta1 at the mRNA and/or protein levels.18,19 Taken together, these findings elucidate the cell cycle– and DNA-directed actions of this agent.

The recent discovery that gossypol mimics a BH3 binding protein has focused investigations on the role of this alkaloid on antiapoptotic proteins. For example, nuclear magnetic resonance– based methods and fluorescence polarization displacement assays have established that gossypol and its analogs bind and interact with the antiapoptotic proteins BCL-2 and BCL-XL.20 In concert with this observation, gossypol induced apoptosis in colon carcinoma cells ectopically expressing BCL-2 and BCL-XL.21 Similarly, gossypol treatment induced cytochrome c release and BAK activation in whole cells as well as in isolated mitochondria that expressed high levels of BCL-2.22 In PC-3 cells, gossypol induced apoptosis by inhibiting the heterodimerization of BCL-XL/BCL-2 with proapoptotic molecules which involves the release of apoptosis-inducing factor (AIF) from mitochondria into the cytosol.23 Further studies showed that gossypol could also induce BAX/BAK–independent activation of apoptosis and cytochrome c release via a conformational change in BCL-2.24 Recent work on head and neck squamous cell carcinoma cells with high endogenous BCL-XL demonstrated that gossypol binds to this protein and that the apoptosis was related to the ratio of BCL-XL and BCL-XS.25 In HL-60 cells, the cytotoxicity occurs through mitochondrial dysfunction pathway.26 In addition to this mitochondrial cell death pathway, an extrinsic cell death pathway through
up-regulation of Fas/Fas ligand has been reported.\(^\text{27}\) Taken together, these recent findings identified gossypol as a BH3 mimic with profound cytotoxicity in cells that express a high level of anti-apoptotic proteins.

These investigations were done in rapidly dividing cell lines, making it challenging to interpret gossypol’s exclusive effect on antiapoptotic proteins since DNA-dependent and cell cycle-regulated actions may also play a role in cell death.

Circulating mature B lymphocytes from patients with chronic lymphocytic leukemia (CLL) are replicationally quiescent, accumulate in bone marrow and blood due to their long survival,\(^\text{28}\) and represent an example of a malignancy caused by failure of programmed cell death.\(^\text{29}\) Therefore, we hypothesized that these cells are an ideal model system for investigating the cytotoxicity and mechanism of action of gossypol.\(^\text{30}\)

Methods

A racemic mixture of gossypol, mainly the (-)-isomer, was provided by Bioenvision, New York, NY. Z-V-AD.fmk was obtained from MP Biomedicals (Solon, OH), glutathione was purchased from Sigma-Aldrich (St Louis, MO), calpeptin was obtained from EMD Biosciences (La Jolla, CA), and N-acetyl cysteine was procured from Calbiochem (San Diego, CA). All other chemicals were reagent grade.

Patients

Leukemic lymphocytes obtained from patients with CLL (n = 50) were incubated in vitro with gossypol and used for different pharmacological, biochemical, and molecular end points. Most patients (70%) were previously untreated and generally had a high white blood cell count in the peripheral blood (Table S1 available on the Blood website; see the Supplemental Materials link at the top of the online article). All patients provided written informed consent to participate in this laboratory protocol, which was approved by the institutional review board of the University of Texas M. D. Anderson Cancer Center in accordance with the Declaration of Helsinki.

Isolation of lymphocytes

Whole blood was collected in heparinized tubes and processed to obtain mononuclear cells (leukemic lymphocytes). Cells were washed twice with cold phosphate-buffered saline (PBS) and resuspended in 10 mL of RPMI 1640 medium supplemented with 10% fetal bovine serum. A Coulter Channelizer (Coulter Electronics, Hialeah, FL) was used to determine the cell number and mean cell volume. The lymphocytes were resuspended at a concentration of 1 × 10⁷ cells/mL and were used fresh for all experiments.

Incubation of lymphocytes

Lymphocytes were incubated with gossypol at the indicated concentrations and times for different assays. To inhibit caspasms, the pan-specific caspase inhibitor Z-V-AD.fmk was used at 50 μM, and to inhibit the generation of ROS, N-acetyl cysteine (NAC; 1 mM) was used. Cells were incubated with these inhibitors 2 hours before the addition of gossypol, and this was followed by 24-hour incubation with both the inhibitors and gossypol.

Apoptosis assays

Apoptosis was measured in annexin V binding assay using a detection kit I from Pharmingen (San Diego, CA) according to the manufacturer’s instructions. Briefly, cells were washed with PBS and resuspended in 200 μL of 1 × annexin binding buffer (BD Biosciences, Franklin Lakes, NJ) at a concentration of 1 × 10⁶ cells/mL. Annexin V–fluorescein isothiocyanate (FITC; 5 μL) was added, and the cells were incubated in the dark for 15 minutes at room temperature. To these labeled cells, 10 μL propidium iodide (50 μg/mL) was added, and flow cytometry was performed immediately (FACSCalibur; Becton, Dickinson, San Jose, CA). Data from at least 10 000 events per sample were recorded and processed using CellQuest software (Becton Dickinson). As another measure of apoptosis, poly(ADP-ribose) polymerase (PARP) cleavage was measured by immunoblotting.

Quantitation of cellular ATP pool

Before and after gossypol treatment, the cells were processed to extract nucleotides. The cellular adenosine triphosphate (ATP) pool was determined using a high-pressure liquid chromatography procedure as described before.\(^\text{31}\) The cellular ATP concentration was between 3 and 4 mM in untreated CLL lymphocytes. Data were expressed as the percentage of the control concentration after drug treatment.

Determination of mitochondrial outer membrane permeabilization

Before and after gossypol treatment, 10⁶ cells were washed in PBS, resuspended in medium, and incubated with tetramethylrhodamine methyl ester (TMRM; Invitrogen, Carlsbad, CA) and FITC-conjugated annexin V in the dark for 15 minutes at room temperature.\(^\text{32}\) Samples were analyzed using a FACSCalibur flow cytometer. (FL1 = annexin V–FITC; FL2 = TMRM.) Data from at least 10 000 events per sample were recorded and processed using CellQuest software (Becton Dickinson).

Measurement of superoxide generation

The superoxide-mediated oxidation-sensitive fluorescent dye dihydroethidium (DHE; Invitrogen Molecular Probes, Eugene, OR) was used to evaluate intracellular production of superoxide radicals. DHE is cell-permeable and, in the presence of O₂⁻, it is oxidized to fluorescent ethidium, which intercalates into DNA. Briefly, cells were washed once with serum- and phenol red–free medium at the indicated time point and then incubated with 5 μM DHE for 30 minutes in medium. The fluorescence of ethidium was measured using a FACscan flow cytometer supplied with CellQuest software.

Nuclear, cytosolic, and mitochondrial protein extraction

Cytosolic and mitochondrial fractions were isolated from treated and untreated cells. Briefly, 2 × 10⁷ cells were harvested, washed once with cold PBS, and resuspended in 3 volumes of isolation buffer (10 mM Tris-HCl, pH 7.5, 10 mM NaCl, 1.5 mM MgCl₂, 1 mM EDTA, 70 mM sucrose, 210 mM mannitol, and protease inhibitors). After incubating in an ice bath for 10 minutes, the cell suspension was homogenized with 100 strokes in a 2-mL glass homogenizer using pestle A (Dounce homogenizer; Bellco Glass, Vineland, NJ). The samples were centrifuged at 1500g at 4°C for 5 minutes to remove nuclei pellet. The supernatants were centrifuged at 15 000g for 15 minutes to separate the mitochondrial (pellet) and cytosolic fractions (supernatant). Mitochondrial pellets were lysed with TNC buffer\(^\text{13}\) (10 mM Tris acetate, pH 8.0, 0.5% NP-40, 5 mM CaCl₂).

Total cell extraction

Cells were lysed on ice for 20 minutes in lysis buffer containing 25 mM HEPES, pH 7.5, 300 mM NaCl, 1.5 mM MgCl₂, 0.5% sodium deoxycholate, 20 mM glycerophosphate, 1% Triton X-100, 0.1% sodium dodecyl sulfate, 0.2 mM EDTA, pH 8, 0.5 mM dithiothreitol, 1 mM sodium orthovanadate, pH 10, and protease inhibitor. Cells were centrifuged at 14 000g for 10 minutes at 4°C, and the supernatant was removed and stored at –80°C until use.

Immunoblot analysis

Protein content was determined using a DC protein assay kit (Bio-Rad Laboratories, Hercules, CA). Aliquots (30 μg) of total cell protein were boiled with Laemmli sample buffer and loaded onto 8% to 12% sodium dodecyl sulfate–polyacrylamide gels and transferred to nitrocellulose membranes (GE Osmonics Labstore, Minnetonka, MN). Membranes were
untreated cells, cells treated with Z-V AD.fmk alone did not undergo any significant cell death (7% and 9%, respectively). However, incubation of CLL cells with Z-VAD.fmk did not abrogate gossypol-induced cell death (70% and 88%, respectively) in these lymphocytes (Figure 1Bi-iv). When the same concentration of Z-VAD.fmk was tested with fludarabine, as a positive control (10 μM) there was inhibition of apoptosis (without Z-VAD.fmk 15%-25%; with Z-VAD.fmk 7%-15%; n = 3; data not shown) in CLL cells. Similar studies were done in samples from 13 patients, and representative data from 9 patients are presented in Figure 1Bv. Overall, Z-VAD.fmk had no effect in 10 of 13 samples and provided only minor protection in the other 3 samples, suggesting that in most cases, gossypol-induced cell death was caspase-independent.

To assess the role of caspases during early apoptosis, leukemic lymphocytes from 3 patients were incubated with and without Z-VAD.fmk in both the presence and absence of gossypol for 4, 8, and 24 hours. Even at these early time points, Z-VAD.fmk did not abrogate gossypol-induced cell death (Table S2). To further establish that gossypol-induced apoptosis is caspase-independent, we incubated CLL cells for 24 hours with 10 μM and 30 μM gossypol in both the presence and absence of Z-VAD.fmk and monitored them for cleavage of PARP protein (Figure S1). Once again, the presence of Z-VAD.fmk did not protect PARP from gossypol-induced cleavage.

Gossypol-mediated cell death was ROS-independent

Execution of apoptosis by phenolic compounds such as gossypol is closely linked to the disruption of mitochondrial electron transport coupled with the production of superoxide radicals. Thus we tested whether an antioxidant like NAC or glutathione can abrogate gossypol-induced cell death. CLL primary cells (n = 6) were incubated with and without NAC in both the presence and absence of gossypol. NAC alone did not induce significant cell death relative to that in untreated control cells (18% and 21%, respectively). Preincubation of CLL cells with NAC did not abrogate gossypol-induced cell death (75% and 82%, respectively; Figure 1Ci-iv). Data were similar in additional samples (Figure 1Cv) and were also consistent when the other antioxidant, glutathione (1 mM; 2-hour pretreatment), was used (data not shown).

Gossypol induced MOMP in CLL lymphocytes

To determine whether gossypol binding to BCL-2 family proteins would affect mitochondrial outer membrane permeabilization (MOMP), lymphocytes were incubated either alone or with gossypol, and MOMP was measured using TMRM. Untreated cells that tested positive for TMRM became negative for TMRM as the membrane became permeable, as can be seen in Figure 2Ai. Similar studies were done in 15 patient samples, and data from 5 representative patients are presented (Figure 2Aii). In all patients, there was a significant MOMP, with a median of 77% TMRM negativity (range, 54%-93%; n = 15).

Gossypol-induced MOMP was caspase- and ROS-independent

Next we assessed whether Z-VAD.fmk could abrogate the MOMP caused by gossypol in CLL primary cells (n = 15). As in untreated cells, cells treated with Z-VAD.fmk alone did not undergo significant permeabilization. Treatment with gossypol alone and with Z-VAD + gossypol resulted in a similar extent of MOMP, suggesting that the gossypol-induced MOMP is caspase
Figure 1. Gossypol-mediated CLL lymphocyte cell death and effect of caspase inhibitor or an antioxidant. (A) Gossypol induces cell death in chronic lymphocytic leukemia (CLL) lymphocytes. CLL primary cells were cultured for 24 hours either (i) alone (control) or (ii) with 30 μM gossypol, and the cell viability was determined by flow cytometry after double staining with FITC-conjugated annexin V and propidium iodide. (iii) Percentage of cell death in CLL primary cells from 9 individual patients treated with gossypol for the indicated times. (iv) CLL primary cells were incubated with 10 and 30 μM gossypol for the indicated times. Cells were lysed and cleavage of PARP was measured by immunoblotting. Actin was used as a loading control. Similar experiments were done in 8 patients, and data from 2 representative patients are shown. (B) Effect of caspase inhibitor on gossypol-induced cell death. CLL primary cells were incubated (i) for 24 hours alone (control), (ii) with Z-VAD.fmk, (iii) with 30 μM gossypol plus Z-VAD.fmk, or (iv) with 30 μM gossypol for 24 hours, and then the cell viability was determined as described in panel A. (v) Percentage of cell death in CLL primary cells from 9 individual patients treated with Z-VAD.fmk and gossypol (C, untreated control; Z, Z-VAD.fmk; Z + G, Z-VAD.fmk plus gossypol; G, gossypol). (C) Effect of antioxidant (NAC) on gossypol (G)–induced cell death. CLL primary cells were incubated (i) for 24 hours alone (control), (ii) with NAC, (iii) with 30 μM gossypol plus NAC, or (iv) with 30 μM gossypol, and then the cell viability was determined as described in panel A. (v) Percentage of cell death in CLL primary cells from 6 individual patients treated with NAC plus gossypol (Con, untreated control).
independent (Figure 2B). Similarly, preincubation of CLL cells with NAC (1 mM) did not protect the cells from gossypol-induced MOMP, as shown for 6 patients’ samples (Figure 2C). These results were similar in all patients, suggesting that superoxide production is also not the mechanism underlying the gossypol-induced MOMP. Furthermore, preincubation with the other antioxidant, glutathione, did not have any protective effect on gossypol-induced MOMP in these lymphocytes (data not shown). These data suggest that the mitochondrial membrane is one of the direct targets of gossypol.

**Temporal relationship between cell death and MOMP**

To elucidate whether the MOMP and induction of cell death occur in parallel or consecutively, we compared time-dependent cell death (Figure 3A) and MOMP (Figure 3B). Data from the same 3 patients’ samples suggested that cell death remained nearly at basal levels after 4 and 8 hours but increased dramatically at 24 hours. In contrast, MOMP was quantifiable as early as 4 hours and gradually increased with time, suggesting that MOMP is an earlier event, whereas cell death follows later. To further ascertain the MOMP, the intracellular concentration of endogenous ATP and its loss were quantitated before and after treatment with gossypol for various times (Figure S2). The ATP pool decreased from 3 to 4 mM (100% value) to less than 100 μM during the 24 hours of incubation in a time-dependent manner. The loss was apparent as early as 4 hours. Again, this dissipation of ATP was not due to cell death; instead, it was due to MOMP, which occurred in as early as 4 hours.
Gossypol increased the production of superoxide in CLL lymphocytes

Given the paradoxic effects of phenolic compounds in oxidative stress, previous studies have evaluated the pro-oxidant property of gossypol in the production of superoxide radicals. When we incubated lymphocytes for 24 hours either alone or with 30 μM gossypol, the production of superoxide radicals increased significantly (Figure 4A). Furthermore, as in the untreated cells (Figure 4Bi), superoxide production was not increased significantly by either Z-V AD.fmk (Figure 4Bii) or NAC (Figure 4Biii), and neither of those agents abrogated gossypol-induced superoxide production (Figure 4Biv-vi). Results were similar in samples from 15 patients.

Effect of gossypol on the levels of antiapoptotic proteins

To determine whether gossypol modulates the expression level of proteins important in the survival of B-CLL cells, we focused on the expression of the antiapoptotic proteins MCL-1, BCL-2, and BCL-XL. Gossypol did not affect the expression of these proteins at early time points (4 and 8 hours) but caused a decrease (ranging from minor to profound) in the level of MCL-1 at 24 hours. Similar experiments were done in samples from 8 patients, and data from 3 representative patients are provided (Figure 5A-C). Since gossypol is a BH3 mimetic, we wanted to test if gossypol treatment and its interactions with antiapoptotic proteins cause displacement of MCL-1 and BCL-2 into cytosol. Immunoblot data (Figure S3) confirmed that these antiapoptotic proteins were not displaced into cytosol at any time after gossypol treatment, although there was abundant of these proteins present in whole cell extract (WCE; Figure S3).

BAX translocation after gossypol treatment

BAX, a proapoptotic protein, has been shown to be the key factor for activation of the intrinsic cell death pathway, which occurs after the binding of BH3 small-molecule inhibitors to members of the BCL-2 family. To test whether that also happens with gossypol, CLL cells were treated with 2 concentrations of gossypol, and the mitochondrial and cytosolic fractions were separated. As Figure 6A
confocal microscopy. FITC-conjugated secondary antibody (green), and the images were captured on
then subjected to fluorescent staining with DAPI (nuclear staining, blue) and
with 10
VDAC, and histone 1 (cytosolic, mitochondrial, and nuclear loading controls,
loaded on lane 8) was analyzed in the nuclear fraction by immunoblotting. GAPDH,
expression of AIF (the last lane is spliced from the same gel which was originally
were treated with 10
M gossypol for 24 hours, and the expression of cytochrome c (CYTO C), BAX
(Figure 6A). It has been shown that AIF is synthesized as an
~67-kDa protein with an N-terminal presequence of 101 residues
that is proteolytically removed upon translocation into the mitochon-
dria to generate the mature ~57-kDa protein.38 In our studies we
tested for both of these AIF fragments using different antibodies
and interestingly AIF ~67-kDa was not detected in the cytosol;
however, there was release of AIF ~57-kDa into cytosol in
concentration and time dependent manner after gossypol treatment.
This finding is consistent with other reports.38,39 To ascertain the
fate of AIF, we performed immunoblotting on the nuclear fraction
in a concentration-dependent manner after treatment with gossypol,
suggesting that either AIF mediated pathway is responsible for
induced by gossypol in presence of calpeptin (data not shown)
mediated by AIF. To further confirm this effect, cell death studies
were done after treatment with gossypol in presence and absence
of calpeptin, however, there was release of AIF
translocated into the nucleus gradually by 24 hours after treatment with 30 µM gossypol (Figure 6B).
Immunohistochemical staining further established that AIF
translocates from the mitochondria to the nucleus. CLL cells were
incubated with 10 µM and 30 µM gossypol for 24 hours, stained
with DAPI and anti-AIF antibody, and then examined with a
confocal microscope. In gossypol-treated cells, AIF translocated
into the nucleus in a concentration-dependent manner. This testing
was performed in samples from 4 patients; data from 1 representa-
tive patient is presented in Figure 6C.

Effect of calpeptin, a calpain inhibitor, on gossypol-induced AIF release
The release of AIF into the cytosol is associated with caspase-independent apoptosis and occurs after calpain activation.40 Since
our studies showed that gossypol-induced apoptosis was caspase independent, we focused on the vital role of AIF in gossypol-
induced apoptosis. To test this, we incubated CLL primary cells for
24 hours alone, with calpeptin, with calpeptin for 2 hours followed
by gossypol, or with gossypol alone and then examined AIF
~67-kDa expression in the cytosolic, mitochondrial, and nuclear
fractions (Figure 7). In the presence of calpeptin, significantly less
AIF was released into the cytosol than with gossypol alone,
suggesting that gossypol-induced cell death is at least partly
mediated by AIF. To further confirm this effect, cell death studies
were done after treatment with gossypol in presence and absence of
calpeptin. However, there was only partial inhibition of apoptosis
induced by gossypol in presence of calpeptin (data not shown)
suggesting that either AIF mediated pathway is responsible for

Effect of gossypol on release of proapoptotic protein
Because gossypol treatment resulted in the MOMP, we examined
the fate of proapoptotic proteins that are localized in the inter-
membranous space of the mitochondria. When CLL lymphocytes
were incubated with 10 µM and 30 µM gossypol, the cytochrome c
level decreased in the mitochondrial fraction but simultaneously
increased in the cytosol (Figure 6A first 2 rows). The release of
cytochrome c was both time and dose dependent. Similar experiments were done in samples from 3 patients.

Loss of AIF from mitochondria and translocation to nucleus
Immunoblotting showed that initially, the amount of AIF in the
mitochondrial fraction of untreated cells was abundant, but it
decreased significantly after treatment with gossypol for 24 hours (Figure 6A). It has been shown that AIF is synthesized as an
~67-kDa protein with an N-terminal presequence of 101 residues
that is proteolytically removed upon translocation into the mitochon-
dria to generate the mature ~57-kDa protein.38 In our studies we
tested for both of these AIF fragments using different antibodies
and interestingly AIF ~67-kDa was not detected in the cytosol;
however, there was release of AIF ~57-kDa into cytosol in
concentration and time dependent manner after gossypol treatment.
This finding is consistent with other reports.38,39 To ascertain the
fate of AIF, we performed immunoblotting on the nuclear fraction
in a concentration-dependent manner after treatment with gossypol,
suggesting that either AIF mediated pathway is responsible for

Figure 6. Effect of gossypol on release and translocation of proapoptotic proteins. (A) Gossypol induces the release of proapoptotic proteins in CLL primary cells. CLL primary cells were treated with 10 µM or 30 µM gossypol for indicated hours, and the expression of cytochrome c (CYTO C), BAX (in mitochondrial BAX, the last 3 lanes were spliced from the same gel which was originally loaded on the first 3 lanes. A vertical line is inserted to indicate a repositioned gel lane, and apoptosis-
inducing factor (AIF) ~57-kDa (amino acids-1-300) and AIF ~67-kDa (amino acids 517-531) were analyzed. GAPDH, VDAC, and Histone 1 (cytosolic, mitochondrial, and nuclear loading controls, respectively) were evaluated by immunoblotting in
cytosolic (C) and mitochondrial (M) fractions. Similar experiments were done in 5 patients, and the immunoblot from 1 representative patient is provided. (B) Translo-
cation of AIF to the nucleus in gossypol-treated CLL primary cells. CLL primary cells were treated with 10 µM or 30 µM gossypol for 4, 8, and 24 hours, and the expression of AIF (the last lane is spliced from the same gel which was originally loaded on lane 8) was analyzed in the nuclear fraction by immunoblotting. GAPDH, VDAC, and Histone 1 (cytosolic, mitochondrial, and nuclear loading controls, respectively) were used as loading controls. (C) CLL primary cells were incubated with 10 µM and 30 µM gossypol for 24 hours, stained with anti-AIF antibody, and then subjected to fluorescent staining with DAPI (nuclear staining, blue) and FITC-conjugated secondary antibody (green), and the images were captured on
confocal microscopy.

illustrates, the level of BAX in the cytosol decreased after
treatment and it is translocated to mitochondria in concentration and time dependent manner after treatment with gossypol, suggest-
ing that BAX activation is involved in the release of proapoptotic molecules.
cytochrome c release caused by disruption of the mitochondrial membranes, thereby making these proteins unavailable to protect the mitochondria from ROS. This may contribute to apoptosis induction under both physiologic and pathologic conditions.

Discussion

In this study, we demonstrated that gossypol induced apoptosis in CLL primary cells. Because primary CLL lymphocytes are quiescent, gossypol’s DNA synthesis and cell cycle–directed actions would not occur in this replicationally null background system. Since gossypol is an antiapoptotic BCL-2 family antagonist, and the pattern of BCL-2 family gene expression in leukemic CD5+ B-CLL cells is skewed toward prevention of apoptosis and the relentless accumulation of CD5+ leukemic B cells, this disease type provides an ideal system for investigating the actions of gossypol that stem from inhibition of BCL-2 antiapoptotic family members. With this respect, the apoptosis was observed in all samples studied, albeit at different levels, which was not dependent on the disease (Rai) stage, prior therapy, refractory disease, and time-dependent manner after gossypol treatment. Because AIF is synthesized as an inactive state and, in response to various stimuli, it undergoes specific conformational changes that allow its targeting and insertion into the mitochondrial outer membrane, where it forms a pore that allows the release of proapoptotic factors into the cytosol. This permeabilization function of BAX is dependent on the BAX-associated production of ROS. Consistent with these findings, our data showed that when CLL lymphocytes were incubated with 30 μM gossypol, BAX translocated from the cytosol to the mitochondria and proapoptotic proteins such as cytochrome c and AIF were liberated in as early as 4 hours.

Release of cytochrome c from the mitochondria is regulated by BCL-2 family proteins with the essential requirement of BAX/Bak. Cytochrome c release, which we also observed in this study, has been identified as the key event in the formation of apoptosomes and the activation of caspase 9. Although we had insufficient numbers of cells to investigate caspase activation, it is highly likely that at least in part; gossypol-induced cell death involves the apoptosome-mediated death cascade. Because inhibition of caspases did not affect cell death generated by gossypol, the apoptosomal pathway does not appear to be the primary mechanism of lymphocyte demise.

The most notable factor involved in the induction of apoptosis, AIF, which is a death-executing molecule that induces caspase-independent cell death, is released into the cytosol through mitochondrial permeability transition pores that involve voltage-dependent anion channels in the outer membrane. Under pathologic conditions, AIF is released from the mitochondria and translocated into the nucleus, where it induces large-scale DNA fragmentation. Translocation of AIF into the nucleus in dying cells has been observed in many models of disease and cell death. It has been shown that AIF is synthesized as an ~67-kDa protein with an N-terminal presequence of 101 residues that is proteolytically removed upon translocation into the mitochondria to generate the mature ~57-kDa protein. In concert with those findings, in our studies when we tested for both of these AIF fragments, AIF ~67-kDa was not detected in the cytosol; however, there was release of AIF ~57-kDa into cytosol in concentration and time dependent manner after gossypol treatment. Because AIF acts as an endonuclease, it does not require an active caspase system. Since caspase inhibition did not protect the cells against gossypol-induced death, it is highly likely that AIF is the primary executor of cell death in CLL lymphocytes after gossypol treatment. As in previous studies, which reported that inhibition of calpain activation by calpeptin precluded AIF release, we also found that the presence of calpeptin and CaCl2 inhibited the release of AIF.
of AIF, demonstrating that proteolytic activity was required for its release.40

In conclusion, our data in CLL lymphocytes obtained from 50 patients with CLL demonstrated that gossypol is an effective cytotoxic agent for this disease. The chief and initiating event appears to be MOMP, which leads to the release of proapoptotic proteins. Primary among these proteins is AIF, which may be responsible for the caspase-independent cell death of these replication-quietous CLL lymphocytes.

Acknowledgments

The authors thank Karen F. Phillips for critically reading and reviewing the manuscript.

This work was supported in part by grants from the National Cancer Institute, Department of Health and Human Services (CA57629, CA81534, and Cancer Center Support Grant P30-16672), CLL Global Research Foundation–US/European Alliance, and Bioenvision, Inc.

References


Gossypol, a BH3 mimetic, induces apoptosis in chronic lymphocytic leukemia cells

Kumudha Balakrishnan, William G. Wierda, Michael J. Keating and Varsha Gandhi

Updated information and services can be found at:
http://www.bloodjournal.org/content/112/5/1971.full.html

Articles on similar topics can be found in the following Blood collections
Neoplasia (4182 articles)

Information about reproducing this article in parts or in its entirety may be found online at:
http://www.bloodjournal.org/site/misc/rights.xhtml#repub_requests

Information about ordering reprints may be found online at:
http://www.bloodjournal.org/site/misc/rights.xhtml#reprints

Information about subscriptions and ASH membership may be found online at:
http://www.bloodjournal.org/site/subscriptions/index.xhtml